

***Fiscal Year 2024 Department of Defense Rare Cancers Research Program
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Concept Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524RCRPCA</p>	<p>Investigators at or above the level of postdoctoral fellow</p>	<ul style="list-style-type: none"> • Supports high-risk/high-reward research that is in the earliest stages of idea development or an untested theory that addresses an important problem related to rare cancers. Proof-of-concept is the anticipated outcome. • Reviewers will be blinded to the identity of the Principal Investigator, collaborators and their organization(s). • Submission must address at least one of the FY24 focus areas of Biology and Etiology, Research Model, and/or Therapy. • Preliminary data are not required. • Clinical trials are not allowed. • <i>Submission of a letter of intent is required prior to full application submission.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$100,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Preproposal): July 15, 2024 5:00 p.m. Eastern time</p> <p>Application: August 26, 2024 11:59 p.m. Eastern time</p>
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524RCRPIDA</p>	<p>Investigators at or above the level of Assistant Professor</p>	<ul style="list-style-type: none"> • Supports high-risk/high-reward research with the potential to yield impactful data in the rare cancers field. • Submission must address at least one of the FY24 focus areas of Biology and Etiology, Research Model, and/or Therapy. • Preliminary data with disease-specific rationale (may include correlatives studies to ongoing clinical research) to support the feasibility of the research hypotheses and research approaches are required; however, these data may be derived from studies of the proposed rare cancer type(s)/subtype(s) under study. • Clinical trials are not allowed. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$350,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): June 17, 2024 5:00 p.m. Eastern time</p> <p>Application: September 23, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Resource and Community Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942524RCRPRCDA</p>	<p>Investigators at or above the level of Assistant Professor</p>	<ul style="list-style-type: none"> • Supports platform development or infrastructure that can be applied to type(s) or sub-type(s) of rare cancers. • Research must emphasize research resources development to facilitate collaboration and information sharing among stakeholders such as researchers, patients, family members, caregivers, clinicians and other members of the rare cancers community. • Preliminary data are not required but may be included (translational research and clinical studies may be included). • Submission must address the FY24 focus area of Platform Development. • Clinical trials are not allowed. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$800,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): June 17, 2024 5:00 p.m. Eastern time</p> <p>Application: September 23, 2024 11:59 p.m. Eastern time</p>